Cited 3 times in
Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn's Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고홍 | - |
dc.contributor.author | 김승 | - |
dc.date.accessioned | 2022-12-22T01:23:09Z | - |
dc.date.available | 2022-12-22T01:23:09Z | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191188 | - |
dc.description.abstract | Background/aims: : Although mucosal healing (MH) is acknowledged as the treatment target in the treat-to-target era, there are limitations on repeated endoscopic examinations, especially in pediatric patients. We aimed to investigate whether fecal calprotectin (FC) could serve as a surrogate marker for the assessment of MH in pediatric patients with Crohn's disease (CD) who have achieved sustained clinical remission (CR) while treated with anti-tumor necrosis factor (TNF) agents. Methods: This multicenter retrospective cross-sectional study included pediatric CD patients who had sustained a CR for at least 6 months with anti-TNF agents and who simultaneously underwent ileocolonoscopy and FC tests during follow-up. MH was defined as the absence of any ulcer on ileocolonoscopy. Results: A total of 131 patients were included in this study. MH was observed in 87 patients (66.7%). The FC level was significantly lower in patients with MH than in those without MH (median 49.0 mg/kg vs 599.0 mg/kg; p<0.001). According to the multivariate logistic regression analysis, FC was the only factor associated with MH (odds ratio, 0.62; 95% confidence interval [CI], 0.52 to 0.73; p<0.001). According to the receiver operating characteristic curve analysis, the optimal cutoff value for FC for the association with MH was <140 mg/kg (area under the curve 0.890, 95% CI 0.829 to 0.951, sensitivity 78.2%, specificity 88.6%, p<0.001). Conclusions: FC was associated with MH in pediatric patients with CD who had achieved a sustained CR for at least 6 months with anti-TNF agents. In these patients, FC can be used to stratify patients and guide decisions regarding ileocolonoscopy in the treat-to-target era. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Editorial Office of Gut and Liver | - |
dc.relation.isPartOf | GUT AND LIVER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Biomarkers / analysis | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Crohn Disease* / drug therapy | - |
dc.subject.MESH | Crohn Disease* / pathology | - |
dc.subject.MESH | Cross-Sectional Studies | - |
dc.subject.MESH | Feces / chemistry | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infliximab / therapeutic use | - |
dc.subject.MESH | Intestinal Mucosa / pathology* | - |
dc.subject.MESH | Leukocyte L1 Antigen Complex / analysis* | - |
dc.subject.MESH | Remission Induction | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Severity of Illness Index | - |
dc.subject.MESH | Tumor Necrosis Factor Inhibitors* / therapeutic use | - |
dc.title | Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn's Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아과학교실) | - |
dc.contributor.googleauthor | Yoo Min Lee | - |
dc.contributor.googleauthor | Sujin Choi | - |
dc.contributor.googleauthor | Byung-Ho Choe | - |
dc.contributor.googleauthor | Hyo-Jeong Jang | - |
dc.contributor.googleauthor | Seung Kim | - |
dc.contributor.googleauthor | Hong Koh | - |
dc.contributor.googleauthor | Eun Sil Kim | - |
dc.contributor.googleauthor | Mi Jin Kim | - |
dc.contributor.googleauthor | Yon Ho Choe | - |
dc.contributor.googleauthor | Ben Kang | - |
dc.identifier.doi | 10.5009/gnl20300 | - |
dc.contributor.localId | A00156 | - |
dc.relation.journalcode | J00954 | - |
dc.identifier.eissn | 2005-1212 | - |
dc.identifier.pmid | 33833135 | - |
dc.subject.keyword | Adalimumab | - |
dc.subject.keyword | Adolescent | - |
dc.subject.keyword | Child | - |
dc.subject.keyword | Crohn disease | - |
dc.subject.keyword | Infliximab | - |
dc.contributor.alternativeName | Koh, Hong | - |
dc.contributor.affiliatedAuthor | 고홍 | - |
dc.citation.volume | 16 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 62 | - |
dc.citation.endPage | 70 | - |
dc.identifier.bibliographicCitation | GUT AND LIVER, Vol.16(1) : 62-70, 2022-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.